In patients with complicated urinary tract infection, clinical and microbiologic treatment success was significantly better with cefepime–taniborbactam (β-lactam and β-lactamase inhibitor) than with meropenem. Read the CERTAIN-1 trial Research Summary: nej.md/3uxZVvK
2
66
182
31K
31
Download Image